Clinical Trials
Participate in groundbreaking research studies that help develop new treatments and medications for various health conditions.
Filter by study
AIM-4
Who is this for?
Those with uncontrolled asthma despite inhaler use
Study:
This study looks at the drug dupilumab. It aims to see how combining dupilumab with inhaled medium dose asthma medication compares to only using high dose inhaled asthma medication on improving asthma symptoms.
ATLAS
Who is this for?
Those with uncontrolled moderate to severe asthma
Study:
This study looks at the drug dupilumab. It aims to evaluate the long term effects (if any) of dupilumab on preventing/slowing the rate of predicted lung function decline.
BRISTOTE
Who is this for?
Those with uncontrolled eosinophilic asthma despite inhaler use
Study:
This study looks at the drug benralizumab. It aims to see how combining benralizumab with inhaled medium dose asthma medication compares to only using high dose inhaled asthma medication on improving asthma symptoms.
FeNO in Asthma Pilot
Who is this for?
Those who are suspected to have asthma, but have normal spirometry results
Study:
This PI-initiated study observes if the immediate measurement of nitric oxide will determine those patients for whom challenge testing should be expedited and those for whom such testing can be deferred.
ASPIRE
Who is this for?
Those with refractory or unexplained chronic cough (cough ≥ 8 weeks)
Study:
This study looks at the drug taplucainium as an inhalation powder. It aims to compare different dosages of the drug on its effectiveness at reducing cough.
CALM-2
Who is this for?
Those with refractory or unexplained chronic cough (cough ≥ 8 weeks)
Study:
This study looks at the drug BLU-5937. It aims to assess its safety and effectiveness at reducing cough.
MIRANDA
Who is this for?
Those with symptomatic COPD (have had ≥2 moderate OR ≥ 1 severe exacerbations in the past year)
Study:
This study looks at the drug tozorakimab. It aims to evaluate the safety and efficacy of adding tozorakimab alongside current standard of care medications on improving COPD symptoms.
ALOFT-PPF
Who is this for?
Those with progressive pulmonary fibrosis (PPF)
Study:
This study looks at the drug BMS-986278. It aims to evaluate its safety, tolerability and efficacy.
ALOFT-IPF
Who is this for?
Those with idiopathic pulmonary fibrosis (IPF)
Study:
This study looks at the drug BMS-986278. It aims to evaluate the efficacy of two different doses of the investigational drug, as well as its safety and tolerability.
OCEAN
Who is this for?
Those with relapsing or refractory eosinophilic granulomatosis with poyangiitis (EGPA) on current standard of care therapy
Study:
This study looks at the drug depemokimab. It aims to observe the efficacy of the investigational drug compared to mepolizumab in EGPA remission.
WAVE
Who is this for?
Healthy and/or those with mild lung/liver damage alpha-1 antirypsin deficiency patients with a ZZ genotype
Study:
This study looks at the drug WVE-006. It aims to assess the safety, tolerability, pharmacodynamics and pharmacokinetics in single and multiple ascending doses of the investigational drug.
REDWOOD-LIVER
Who is this for?
Alpha-1 antitrypsin deficiency patients with a ZZ genotype and moderate-severe liver fibrosis
Study:
This study looks at the drug fazirsiran. It aims to observe the efficacy of the investigational drug compared to placebo at improving AATD induced liver fibrosis.
REDWOOD-LUNG
Who is this for?
Alpha-1 antitrypsin deficiency patients with a ZZ genotype and mild liver fibrosis
Study:
This study looks at the drug fazirsiran. It aims to observe the safety, tolerability and efficacy of the investigational drug. It will look at any effects on lung function and liver scarring.
Participating in a Clinical Trial
Benefits
- Access to new treatments before they're widely available
- Regular and careful medical attention from research staff
- Helping to advance medical knowledge
- Potential compensation for time and travel
Considerations
- Possible side effects or risks from experimental treatments
- Time commitment for appointments and procedures
- May require stopping current medications
- No guarantee the experimental treatment will work
Our Commitment
- Full disclosure of potential risks and benefits
- Comprehensive informed consent process
- Right to withdraw from the study at any time
- Ongoing monitoring of your health and safety
Interested in Participating?
If you're interested in participating in a clinical trial, please contact our research team for more information about current opportunities and the enrollment process.
Contact Our Research Team